BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Au KM, Tripathy A, Lin CP, Wagner K, Hong S, Wang AZ, Park SI. Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma. ACS Nano 2018;12:1544-63. [PMID: 29361211 DOI: 10.1021/acsnano.7b08122] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Poulie CBM, Sporer E, Hvass L, Jørgensen JT, Kempen PJ, Lopes van den Broek SI, Shalgunov V, Kjaer A, Jensen AI, Herth MM. Bioorthogonal Click of Colloidal Gold Nanoparticles to Antibodies In vivo. Chemistry 2022;28:e202201847. [PMID: 35851967 DOI: 10.1002/chem.202201847] [Reference Citation Analysis]
2 Cheal SM, Chung SK, Vaughn BA, Cheung NV, Larson SM. Pretargeting: A Path Forward for Radioimmunotherapy. J Nucl Med 2022;63:1302-15. [DOI: 10.2967/jnumed.121.262186] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Caers J, Duray E, Vrancken L, Marcion G, Bocuzzi V, De Veirman K, Krasniqi A, Lejeune M, Withofs N, Devoogdt N, Dumoulin M, Karlström AE, D’huyvetter M. Radiotheranostic Agents in Hematological Malignancies. Front Immunol 2022;13:911080. [DOI: 10.3389/fimmu.2022.911080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Huang Z, Hu Y, Yang Y, Huang W, Wang Y, Ye D. Recent Advances in Pretargeted Imaging of Tumors in Vivo. Analysis & Sensing 2022;2. [DOI: 10.1002/anse.202200013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Mahajan S, Aalhate M, Guru SK, Singh PK. Nanomedicine as a magic bullet for combating lymphoma. J Control Release 2022;347:211-36. [PMID: 35533946 DOI: 10.1016/j.jconrel.2022.05.002] [Reference Citation Analysis]
6 Kwak E, Kim T, Yang K, Kim YM, Han HS, Park KH, Choi KY, Roh YH. Surface-Functionalized Polymeric siRNA Nanoparticles for Tunable Targeting and Intracellular Delivery to Hematologic Cancer Cells. Biomacromolecules 2022. [PMID: 35362323 DOI: 10.1021/acs.biomac.1c01497] [Reference Citation Analysis]
7 Au KM, Tisch R, Wang AZ. Immune Checkpoint Ligand Bioengineered Schwann Cells as Antigen-Specific Therapy for Experimental Autoimmune Encephalomyelitis. Adv Mater 2022;34:e2107392. [PMID: 34775659 DOI: 10.1002/adma.202107392] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Au KM, Tisch R, Wang AZ. In Vivo Bioengineering of Beta Cells with Immune Checkpoint Ligand as a Treatment for Early-Onset Type 1 Diabetes Mellitus. ACS Nano 2021;15:19990-20002. [PMID: 34843648 DOI: 10.1021/acsnano.1c07538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Taiariol L, Chaix C, Farre C, Moreau E. Click and Bioorthogonal Chemistry: The Future of Active Targeting of Nanoparticles for Nanomedicines? Chem Rev 2021. [PMID: 34705429 DOI: 10.1021/acs.chemrev.1c00484] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
10 Gu W, Qu R, Meng F, Cornelissen JJLM, Zhong Z. Polymeric nanomedicines targeting hematological malignancies. J Control Release 2021;337:571-88. [PMID: 34364920 DOI: 10.1016/j.jconrel.2021.08.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
11 Handula M, Chen KT, Seimbille Y. IEDDA: An Attractive Bioorthogonal Reaction for Biomedical Applications. Molecules 2021;26:4640. [PMID: 34361793 DOI: 10.3390/molecules26154640] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
12 Gao Y, Chen L, Ge J, Cui J, Zeng J, Gao M. A Pretargeting Strategy Enabled by Bioorthogonal Reactions Towards Advanced Nuclear Medicines: Application and Perspective. Chem Res Chin Univ 2021;37:870-9. [DOI: 10.1007/s40242-021-1179-2] [Reference Citation Analysis]
13 Welling MM, Duszenko N, van Willigen DM, Hensbergen AW, Buckle T, Rietbergen DDD, Roestenberg M, van Leeuwen FWB. Interventional nuclear medicine: "click" chemistry as an in vivo targeting strategy for imaging microspheres and bacteria. Biomater Sci 2021;9:1683-90. [PMID: 33410436 DOI: 10.1039/d0bm01823f] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Idiago-lópez J, Moreno-antolín E, de la Fuente JM, Fratila RM. Nanoparticles and bioorthogonal chemistry joining forces for improved biomedical applications. Nanoscale Adv 2021;3:1261-92. [DOI: 10.1039/d0na00873g] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
15 Hagan CT 4th, Mi Y, Knape NM, Wang AZ. Enhancing Combined Immunotherapy and Radiotherapy through Nanomedicine. Bioconjug Chem 2020;31:2668-78. [PMID: 33251789 DOI: 10.1021/acs.bioconjchem.0c00520] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
16 Porte K, Riberaud M, Châtre R, Audisio D, Papot S, Taran F. Bioorthogonal Reactions in Animals. Chembiochem 2021;22:100-13. [PMID: 32935888 DOI: 10.1002/cbic.202000525] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
17 Castro F, Pinto ML, Pereira CL, Serre K, Barbosa MA, Vermaelen K, Gärtner F, Gonçalves RM, De Wever O, Oliveira MJ. Chitosan/γ-PGA nanoparticles-based immunotherapy as adjuvant to radiotherapy in breast cancer. Biomaterials 2020;257:120218. [DOI: 10.1016/j.biomaterials.2020.120218] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
18 Au KM, Park SI, Wang AZ. Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy. Sci Adv 2020;6:eaba8564. [DOI: 10.1126/sciadv.aba8564] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 10.7] [Reference Citation Analysis]
19 Huang L, Huang J, Huang J, Xue H, Liang Z, Wu J, Chen C. Nanomedicine - a promising therapy for hematological malignancies. Biomater Sci 2020;8:2376-93. [PMID: 32314759 DOI: 10.1039/d0bm00129e] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
20 Au KM, Wang AZ, Park SI. Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin's lymphoma. Sci Adv 2020;6:eaaz9798. [PMID: 32270047 DOI: 10.1126/sciadv.aaz9798] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
21 Rondon A, Degoul F. Antibody Pretargeting Based on Bioorthogonal Click Chemistry for Cancer Imaging and Targeted Radionuclide Therapy. Bioconjug Chem 2020;31:159-73. [PMID: 31855602 DOI: 10.1021/acs.bioconjchem.9b00761] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 11.3] [Reference Citation Analysis]
22 Sun B, Hagan CT 4th, Caster J, Wang AZ. Nanotechnology in Radiation Oncology. Hematol Oncol Clin North Am 2019;33:1071-93. [PMID: 31668207 DOI: 10.1016/j.hoc.2019.08.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
23 Eskian M, Khorasanizadeh M, Zinzani PL, Illidge TM, Rezaei N. Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma. Int Rev Immunol 2019;38:79-91. [PMID: 30931651 DOI: 10.1080/08830185.2019.1588266] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
24 Au KM, Balhorn R, Balhorn MC, Park SI, Wang AZ. High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles. ACS Cent Sci 2019;5:122-44. [PMID: 30693332 DOI: 10.1021/acscentsci.8b00746] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
25 Liu M, Sun Q, Wang J, Wei F, Yang L, Ren X. A new perspective: Exploring future therapeutic strategies for cancer by understanding the dual role of B lymphocytes in tumor immunity. Int J Cancer. 2019;144:2909-2917. [PMID: 30183084 DOI: 10.1002/ijc.31850] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
26 Zhu S, Gu Z, Zhao Y. Harnessing Tumor Microenvironment for Nanoparticle-Mediated Radiotherapy. Adv Therap 2018;1:1800050. [DOI: 10.1002/adtp.201800050] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
27 Stéen EJL, Edem PE, Nørregaard K, Jørgensen JT, Shalgunov V, Kjaer A, Herth MM. Pretargeting in nuclear imaging and radionuclide therapy: Improving efficacy of theranostics and nanomedicines. Biomaterials 2018;179:209-45. [PMID: 30007471 DOI: 10.1016/j.biomaterials.2018.06.021] [Cited by in Crossref: 87] [Cited by in F6Publishing: 91] [Article Influence: 17.4] [Reference Citation Analysis]